Loading
Aurinia Pharmaceuticals Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 02 Jun 2026.
Aurinia Pharmaceuticals Inc.: what insiders have been doing
Aurinia Pharmaceuticals Inc. is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). Between 18 October 2025 and 18 October 2026, 19 insiders published 67 filings.
Both sides are active: 14 purchases worth €22.0M and 2 sales worth €468k, from 2 insiders and 1 insider respectively. Taken together, the purchases exceed the sales by €21.5M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The buyers include 2 senior executives and 1 chief executive. Tang Kevin filed the largest purchase, €4.5M, on 2 June 2026, which represents 0.21% of the company's market value.
The most recent open-market purchase was published on 3 June 2026, 136 days ago. Typically, a trade is published a median of 4 days after it takes place. For comparison, the SEC allows two business days to file a Form 4.
For context, the typical company on the same exchange (median of 5,816 companies) published 19 filings over the same period, against 67 filings here. Looking back to 2021, when coverage begins, insiders filed 31 purchases and 36 sales. The 10-K for the year ended 31 December 2025 shows 287.2 m USD of net income.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Anixa Biosciences Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
174
Thresholds
n/a
Buy Volume
€40M
31 ops. · all time
Sell Volume
€7M
36 ops. · all time
Who traded when
BuySaleTang Kevin11 buys
Kevin Tang8 buys
Keenan Greg2 sales
Stephen P. Robertson2 sales
Since the insiders bought
- +6.8%Entry US$15.67 · Close 15 Oct 2026 US$16.73
- -38.9%Entry US$9.04 · Close at T+365 US$5.52
- +87.9%Entry US$4.88 · Close at T+365 US$9.17
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 1,544 of 24,148 companies
77.3
score / 100
Value65
Quality90
FCF yld6.2%
Earn yld13%
EV/EBITDA16.5x
ROE66%
Gross mgn88%
Net mgn·
Debt/EBITDA0.5x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$16.36
Analyst consensus
7 analysts1.33/5
US$16.00Target US$17.86(+9%)US$21.00
Income statement
RevenueUS$283.1M
Gross profitUS$250.4M88% margin
EBITDAUS$137.9M49% margin
Net incomeUS$287.2M100.8% margin
Valuation
PER (trailing)7.2x
PER (forward)15.3x
P/Book3.5x
Beta1.61
Balance sheet & cash
Market capUS$2.2B
Total debtUS$74.8M
Free Cash FlowUS$135.4M
Debt / Equity10%
Profitability & ownership
ROE66.1%
ROA15.5%
% insiders6.8%
% institutions60.5%
Last declaration on 13 September 2026
Declarations174 total
9,087 shares@ CA$15.950.0047% mcap9.4% of flowCommon SharesTSXSEDI:4777061
21,026 shares@ CA$15.950.011% mcap21.6% of flowRights Performance AwardTSXSEDI:4777060
11,939 shares@ US$15.950.0085% mcap12.1% of flowCommon StockSEC:0001600620-26-000068:0
42,052 shares@ CA$16.970.023% mcap46.0% of flowRights Performance AwardTSXSEDI:4768792
21,077 shares@ CA$16.970.012% mcap23.0% of flowCommon SharesTSXSEDI:4768789
360 sharesCommon SharesTSXSEDI:4768784
20,975 shares@ US$16.970.016% mcap22.5% of flowCommon StockSEC:0001837798-26-000013:0
47,000 shares@ US$15.300.032% mcap100.0% of flowCommonSEC144:0001837798-26-000010
OptionsTSXSEDI:4734885
OptionsTSXSEDI:4734884
Common SharesTSXSEDI:4734882
Common SharesTSXSEDI:4734881
Common SharesTSXSEDI:4734879
Common SharesTSXSEDI:4734876
23,931 shares@ CA$15.670.011% mcap100.0% of flowOptionsTSXSEDI:4731981
23,931 shares@ CA$15.670.011% mcap100.0% of flowOptionsTSXSEDI:4731973
23,931 shares@ CA$15.670.011% mcap100.0% of flowOptionsTSXSEDI:4731965
9,593 shares@ US$16.52140.0077% mcap0.3% of flowCommonSEC144:0001950047-26-005702
25,000 shares@ US$16.33740.020% mcap0.7% of flowCommonSEC144:0001950047-26-005622
OptionsTSXSEDI:4728383
5,000 shares@ CA$1.650.0002% mcap0.1% of flowOptionsTSXSEDI:4728381
OptionsTSXSEDI:4728241
103,002 shares@ CA$15.280.046% mcap12.6% of flowCommon SharesTSXSEDI:4728152
Canonical exit: 31 Aug 2026 (T+90)
49 shares@ CA$15.340.0000% mcap0.0% of flowCommon SharesTSXSEDI:4728150
Canonical exit: 30 Aug 2026 (T+90)
25 of 174 declarations
About Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc. (ticker: AUPH) is a US-listed biopharmaceutical company traded on the NASDAQ in the United States. From an international equity perspective, Aurinia is best understood as a focused specialty pharma business rather than a broad-based drug developer: its core thesis centers on autoimmune and kidney diseases with significant unmet medical need. The company has Canadian historical roots, but its current commercial identity is anchored in the US market and in the lifecycle management of its lead asset, voclosporin.
Aurinia’s key commercial product is LUPKYNIS® (voclosporin), which the company describes as the first FDA-approved oral therapy for adult patients with active lupus nephritis. That approval marked a decisive transition from a development-stage biotech to a commercial-stage biopharmaceutical company with product revenue. The company’s business model is therefore highly concentrated: it focuses on developing, commercializing, and expanding access to therapies for targeted patient populations, particularly in autoimmune and renal disease settings.
Read moreShow less
Competitively, Aurinia operates in a specialized and clinically demanding market. Lupus nephritis is a serious and difficult-to-treat condition, which means market share depends not only on efficacy and safety, but also on physician adoption, reimbursement access, and the company’s ability to execute commercially. Aurinia’s differentiation lies in its oral therapy profile, regulatory positioning, and the fact that it controls a branded product in a niche indication where treatment options remain limited. This concentration can be a strength if adoption continues, but it also creates product-specific risk.
Geographically, Aurinia is primarily centered on North American operations, with the United States as the main commercial and regulatory platform. The company has also sought to broaden the reach of voclosporin beyond the US through international regulatory and partnership pathways, reflecting a broader aspiration to build value across multiple markets. Historically, the business traces back to Isotechnika Pharma Inc., founded in 1993, which gives Aurinia a long development history before the eventual launch of LUPKYNIS.
Recent company disclosures show continued commercial momentum for LUPKYNIS, with year-over-year revenue growth in the latest reported periods. For investors, that is an important signal: Aurinia’s story is increasingly about execution, market penetration, and sustaining the commercial value of an approved therapy rather than binary clinical-stage outcomes. In short, Aurinia is a NASDAQ-listed United States biopharma company with a concentrated but strategically important niche in lupus nephritis and autoimmune disease treatment.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
